[Clindamycin-2-phosphate in the treatment of respiratory infections and its distribution into pleural effusion].
We treated pneumonia due to anaerobic bacteria, Mycoplasma pneumonia, and other type of pneumonia with clindamycin-2-phosphate (CLDM-P) and studied the distribution of the drug into pleural effusion. The obtained results are summarized as follows. 1. CLDM-P showed excellent effects in all the treated cases of pneumonia due to anaerobic bacteria and Mycoplasma pneumonia. But the success rate was 50% in cases of other type of pneumonia. We suggest that the drug must be used in due consideration of the types of causative bacteria. 2. Five cases which had developed pleural effusions were treated with intravenous drip of CLDM-P 1,200 mg in 200 ml electrolytic solution to see the distribution into pleural effusions. The results showed that the distribution ratio was 9.0% on the average. Peak levels were 1.86-6.07 micrograms/ml and the concentration was as high as 1.28 micrograms/ml on the average 24 hours after administration.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D010996:Pleural Effusion / Q000378:metabolism*; D011014:Pneumonia / Q000188:drug therapy* / Q000378:metabolism
D002981:Clindamycin; C007084:clindamycin phosphate